These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 33255854)

  • 1. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    Hottenrott T; Schorb E; Fritsch K; Dersch R; Berger B; Huzly D; Rauer S; Tebartz van Elst L; Endres D; Stich O
    J Neurol; 2018 May; 265(5):1106-1114. PubMed ID: 29511863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
    Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
    Front Neurol; 2019; 10():280. PubMed ID: 30972011
    [No Abstract]   [Full Text] [Related]  

  • 6. The MRZ reaction in primary progressive multiple sclerosis.
    Hottenrott T; Dersch R; Berger B; Rauer S; Huzly D; Stich O
    Fluids Barriers CNS; 2017 Feb; 14(1):2. PubMed ID: 28166789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
    Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
    Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
    Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 10. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
    Jarius S; Eichhorn P; Franciotta D; Petereit HF; Akman-Demir G; Wick M; Wildemann B
    J Neurol; 2017 Mar; 264(3):453-466. PubMed ID: 28005176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis.
    Huss A; Mojib-Yezdani F; Bachhuber F; Fangerau T; Lewerenz J; Otto M; Tumani H; Senel M
    Clin Chim Acta; 2019 Nov; 498():148-153. PubMed ID: 31437445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome.
    Brettschneider J; Tumani H; Kiechle U; Muche R; Richards G; Lehmensiek V; Ludolph AC; Otto M
    PLoS One; 2009 Nov; 4(11):e7638. PubMed ID: 19890384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.
    Hottenrott T; Dersch R; Berger B; Endres D; Huzly D; Thiel J; Rauer S; Stich O; Salzer U; Venhoff N
    BMC Neurol; 2018 Jan; 18(1):14. PubMed ID: 29386006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?
    Jarius S; Eichhorn P; Jacobi C; Wildemann B; Wick M; Voltz R
    J Neurol Sci; 2009 May; 280(1-2):98-100. PubMed ID: 19041103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.